​

Tyra Biosciences (TYRA) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChart

TYRA Stock Forecast

Tyra Biosciences stock forecast is as follows: an average price target of $31.75 (represents a 126.79% upside from TYRA’s last price of $14.00) and a rating consensus of 'Buy', based on 5 wall street analysts offering a 1-year stock forecast.

TYRA Price Target

The average price target for Tyra Biosciences (TYRA) is $31.75 based on 1-year price targets from 5 Wall Street analysts in the past 3 months, with a price target range of $33.00 to $30.00. This represents a potential 126.79% upside from TYRA's last price of $14.00.

TYRA Analyst Ratings

Buy

According to 5 Wall Street analysts, Tyra Biosciences's rating consensus is 'Buy'. The analyst rating breakdown for TYRA stock is 0 'Strong Buy' (0.00%), 5 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Tyra Biosciences Price Target by Analyst

DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Nov 11, 2024Mitchell KapoorH.C. Wainwright$30.00$16.7079.64%114.29%
Oct 18, 2024Jason ZemanskyBank of America Securities$31.00$25.9819.32%121.43%
Sep 19, 2024Matt BieglerOppenheimer$33.00$24.6433.90%135.71%
Aug 15, 2024Christopher RaymondRaymond James$33.00$21.5752.99%135.71%
Aug 08, 2024Mitchell KapoorH.C. Wainwright$25.00$19.5028.21%78.57%
Mar 20, 2024Mitchell KapoorH.C. Wainwright$23.00$17.3732.41%64.29%
Feb 03, 2023Oppenheimer$17.00$13.3027.82%21.43%

The latest Tyra Biosciences stock forecast, released on Nov 11, 2024 by Mitchell Kapoor from H.C. Wainwright, set a price target of $30.00, which represents a 79.64% increase from the stock price at the time of the forecast ($16.70), and a 114.29% increase from TYRA last price ($14.00).

Tyra Biosciences Price Target by Period

1M3M12M
# Anlaysts-36
Avg Price Target-$31.33$29.17
Last Closing Price$14.00$14.00$14.00
Upside/Downside-100.00%123.79%108.36%

In the current month, the average price target of Tyra Biosciences stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Tyra Biosciences's last price of $14.00. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades

DateCompanyPrevious RatingNew RatingRating Change
Oct 18, 2024Bank of America SecuritiesBuyUpgrade
Oct 11, 2024Piper SandlerOverweightOverweightHold
Oct 07, 2024H.C. WainwrightBuyBuyHold
Sep 19, 2024OppenheimerOutperformOutperformHold
Aug 15, 2024Piper SandlerOverweightInitialise
Aug 08, 2024H.C. WainwrightBuyBuyHold
Jul 08, 2024Cowen & Co.BuyBuyHold
Jul 03, 2024OppenheimerOutperformOutperformHold
May 10, 2024OppenheimerOutperformOutperformHold
Feb 03, 2023OppenheimerOutperformInitialise

Tyra Biosciences's last stock rating was published by Bank of America Securities on Oct 18, 2024. The company Upgrade its TYRA rating from "null" to "Buy".

Tyra Biosciences Financial Forecast

Tyra Biosciences Revenue Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24
Revenue-----------
Avg Forecast-----------
High Forecast-----------
Low Forecast-----------
# Analysts-----------
Surprise %-----------

Tyra Biosciences's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. TYRA's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).

Tyra Biosciences EBITDA Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24
# Analysts-----------
EBITDA-----------
Avg Forecast-----------
High Forecast-----------
Low Forecast-----------
Surprise %-----------

undefined analysts predict TYRA's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Tyra Biosciences's previous annual EBITDA (undefined) of $NaN.

Tyra Biosciences Net Income Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24
# Analysts-----------
Net Income-----------
Avg Forecast$-31.97M$-29.37M$-28.15M$-29.25M$-32.82M$-31.06M$-30.91M$-28.70M$-28.76M$-23.48M$-23.96M
High Forecast$-31.97M$-29.37M$-28.15M$-29.25M$-32.82M$-31.06M$-30.91M$-25.71M$-24.07M$-23.48M$-23.96M
Low Forecast$-31.97M$-29.37M$-28.15M$-29.25M$-32.82M$-31.06M$-30.91M$-31.69M$-32.87M$-23.48M$-23.96M
Surprise %-----------

Tyra Biosciences's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. TYRA's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).

Tyra Biosciences SG&A Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24
# Analysts-----------
SG&A-----------
Avg Forecast-----------
High Forecast-----------
Low Forecast-----------
Surprise %-----------

Tyra Biosciences's average Quarter SG&A projection for undefined is $NaN, based on undefined Wall Street analysts, with a range of $NaN to $NaN. The forecast indicates a NaN% fall compared to TYRA last annual SG&A of $NaN (undefined).

Tyra Biosciences EPS Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24
# Analysts-----------
EPS-----------
Avg Forecast$-0.54$-0.50$-0.48$-0.50$-0.56$-0.53$-0.53$-0.49$-0.49$-0.40$-0.41
High Forecast$-0.54$-0.50$-0.48$-0.50$-0.56$-0.53$-0.53$-0.44$-0.41$-0.40$-0.41
Low Forecast$-0.54$-0.50$-0.48$-0.50$-0.56$-0.53$-0.53$-0.54$-0.56$-0.40$-0.41
Surprise %-----------

According to undefined Wall Street analysts, Tyra Biosciences's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to TYRA previous annual EPS of $NaN (undefined).

Tyra Biosciences Peer Comparison by Price Target

TickerCompanyLast Closing PriceAvg Price TargetUpside/DownsideAvg Rating
XLOXilio Therapeutics$0.93$7.00652.69%Buy
HOWLWerewolf Therapeutics$1.64$12.00631.71%Buy
MOLNMolecular Partners$5.25$29.00452.38%Buy
CCCCC4 Therapeutics$4.05$20.00393.83%Buy
IPSCCentury Therapeutics$1.17$5.00327.35%Buy
PMVPPMV Pharmaceuticals$1.52$6.00294.74%Buy
CGEMCullinan Oncology$11.49$34.00195.91%Buy
MLYSMineralys Therapeutics$12.35$30.00142.91%Buy
RAPTRAPT Therapeutics$0.84$2.00138.10%Hold
ERASErasca$2.63$6.00128.14%Buy
PHVSPharvaris$18.49$42.00127.15%Buy
STOKStoke Therapeutics$12.10$26.50119.01%Buy
TYRATyra Biosciences$15.22$31.75108.61%Buy
DSGNDesign Therapeutics$6.25$9.6754.72%Buy
EWTXEdgewise Therapeutics$30.17$46.2553.30%Buy
CNTBConnect Biopharma$1.06$1.5041.51%Buy
IKNAIkena Oncology$1.62$1.33-17.90%Buy

TYRA Forecast FAQ

Is Tyra Biosciences a good buy?

Yes, according to 5 Wall Street analysts, Tyra Biosciences (TYRA) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 5 'Buy' recommendations, accounting for 100.00% of TYRA's total ratings.

What is TYRA's price target?

Tyra Biosciences (TYRA) average price target is $31.75 with a range of $30 to $33, implying a 126.79% from its last price of $14. The data is based on 5 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Tyra Biosciences stock go up soon?

According to Wall Street analysts' prediction for TYRA stock, the company can go up by 126.79% (from the last price of $14 to the average price target of $31.75), up by 135.71% based on the highest stock price target, and up by 114.29% based on the lowest stock price target.

Can Tyra Biosciences stock reach $20?

TYRA's average twelve months analyst stock price target of $31.75 supports the claim that Tyra Biosciences can reach $20 in the near future.

What are Tyra Biosciences's analysts' financial forecasts?

Tyra Biosciences's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-123M (high $-120M, low $-126M), average SG&A $0 (high $0, low $0), and average EPS is $-2.097 (high $-2.047, low $-2.148). TYRA's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-119M (high $-119M, low $-119M), average SG&A $0 (high $0, low $0), and average EPS is $-2.017 (high $-2.017, low $-2.017).